Floatz logo

cd1a-car t

Acute T-lymphoblastic Leukemia

The Affiliated Hospital of Xuzhou Medical UniversityCell therapyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Acute T-lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
Chimeric Antigen Receptor Modified T Cells Infusion
Shenzhen Geno-Immune Medical Institute
Phase 2B

Same molecule, other indications

cd1a-car t is also rated in:

Acute T-lymphoblastic LymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
T-lymphoblastic lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
T-cell acute lymphoblastic leukemiaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →